Ventyx Biosciences ended development of an experimental drug for plaque psoriasis though it was safe and moderately effective in a Phase 2 trial. Click here to view original post
Biotech CEOs leading cell and gene therapy companies spoke frankly about the tough choices they’re making to preserve cash. Click here to view original post
Neurocrine Biosciences announced that its experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial of children and adolescents. Click here to view original post
Failure is the norm in biotech; talking about it openly is not. But Histogen’s leadership spoke frankly about the company’s setbacks. Click here to view original post
Cambridge, Dallas, and Washington, D.C. were chosen as the three national hubs for the new federal health research agency ARPA-H. Click here to view original post
Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve been in a decade amid the biotech industry’s ongoing downturn, […]
Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO. The nomination follows a bitter board […]
Dan Worthley, a gastroenterologist and cancer scientist at Colonoscopy Clinic in Brisbane, Australia, does thousands of colonoscopies a year, seeking and destroying precancerous polyps. It’s a practically surefire way to prevent colorectal cancer, but an […]
SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to […]
Micronoma, a San Diego-based biotech startup, was founded on the idea that signatures from microbes that colonize tumors could lead to a blood test to detect cancer. The hypothesis was based on a high-profile Nature […]
SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results […]
Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics company, alleging that they were harassed, that the company failed to take corrective action, and that it retaliated by removing […]
LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators. […]
SAN DIEGO — It was Novo Nordisk’s Ozempic and Wegovy that set off a new era in obesity medicine, delivering unprecedented levels of weight loss and working its way into popular culture, inescapable ads, and […]
SAN DIEGO — Ozempic and Wegovy became weight loss sensations by targeting a single hormone, leading people to lose as much as 15% of their weight. But that wasn’t enough — soon there was Mounjaro, […]
SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks […]
SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and […]
SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity […]
The sudden resignation of Francis deSouza as the CEO of Illumina Sunday represents anything but an orderly transition — and it leaves a black mark on both his six-year tenure and his luckless quest to […]
Just two weeks after surviving an activist investor’s attempt to oust him from Illumina’s board, company CEO Francis deSouza has resigned his roles at the sequencing behemoth, Illumina said Sunday. deSouza stepped down effectively immediately […]
Shareholders in the DNA-sequencing firm Illumina on Thursday voted to replace the company’s chairman with a candidate put forward by the activist investor Carl Icahn, even as Illumina held off an effort to oust other […]
On Thursday Illumina, the largest and most important maker of DNA sequencing technology, whose innovations have changed medicine and have been crucial in our battles with diseases from Covid to cancer, will face a day […]
Brigham and Women’s Hospital will launch a new institute focused on immunology and inflammation, thanks to a $100 million gift, the largest in the hospital’s history. The donation, from Gene Lay, founder and CEO of […]
The Food and Drug Administration warned health care providers Thursday that a security vulnerability in DNA sequencers made by Illumina could allow unauthorized users to access or alter potentially important medical data. The news is […]
Is Illumina the Disney of biotech? Does the Texas two-step work after all? And can you ever really go home again? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech […]
The U.S. Federal Trade Commission on Monday ordered DNA sequencing giant Illumina to divest Grail, a cancer diagnostics firm it purchased without regulatory approval, saying the $7.1 billion acquisition “would stifle competition and innovation in […]
Is AI dictating patient care? What happens when your bank falls apart? And can Illumina endure some shareholder activism? We cover all that and more this week on the 250th episode of “The Readout LOUD,” […]
Illumina, the DNA sequencing giant whose stock has fallen 40% in two years, already had problems. Now it has to contend with Carl Icahn. The granddaddy of activist investors announced Monday morning that he’s taken […]
SAN DIEGO — The first time it happened, veteran real estate broker Ted Jacobs thought it was a fluke. But it didn’t take long for him to realize that the biotech industry’s demand for lab […]
Sanofi’s head of research and development, John Reed, is leaving the pharmaceutical giant to pursue a new opportunity, the company announced Monday. Reed joined Sanofi in 2018, after holding a similar position at Swiss pharma […]
Copyright © 2023 Biotech Networks, LLC
